22 related articles for article (PubMed ID: 36898290)
1. Geographical and spatial disparities in the incidence and survival of rare cancers in Australia.
Dasgupta P; Cameron JK; Cramb SM; Trevithick RW; Aitken JF; Mengersen K; Baade PD
Int J Cancer; 2023 Apr; 152(8):1601-1612. PubMed ID: 36495274
[TBL] [Abstract][Full Text] [Related]
2. Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset.
Ruseckaite R; Beckmann K; O'Callaghan M; Roder D; Moretti K; Zalcberg J; Millar J; Evans S
BMC Res Notes; 2016 Jan; 9():37. PubMed ID: 26801762
[TBL] [Abstract][Full Text] [Related]
3. Multivariate Bayesian meta-analysis: joint modelling of multiple cancer types using summary statistics.
Jahan F; Duncan EW; Cramb SM; Baade PD; Mengersen KL
Int J Health Geogr; 2020 Oct; 19(1):42. PubMed ID: 33069256
[TBL] [Abstract][Full Text] [Related]
4. Regional Variation in Lifetime Probability of Admission to Residential Aged Care in Australia.
Cooper-Stanbury M
J Aging Health; 2024 Apr; ():8982643241248207. PubMed ID: 38769846
[TBL] [Abstract][Full Text] [Related]
5. Changes in prostate specific antigen (PSA) "screening" patterns by geographic region and socio-economic status in Australia: Analysis of medicare data in 50-69 year old men.
Kohar A; Cramb SM; Pickles K; Smith DP; Baade PD
Cancer Epidemiol; 2023 Apr; 83():102338. PubMed ID: 36841020
[TBL] [Abstract][Full Text] [Related]
6. Patterns of prostate-specific antigen testing by remoteness of residence and socio-economic status: An Australian population-based study.
Calopedos RJS; Bang A; Baade P; Yu XQ; Ruthven S; Patel MI; Smith DP
Aust J Rural Health; 2019 Jun; 27(3):216-223. PubMed ID: 31070837
[TBL] [Abstract][Full Text] [Related]
7. Geospatial and temporal variation of prostate cancer incidence.
Wah W; Ahern S; Evans S; Millar J; Evans M; Earnest A
Public Health; 2021 Jan; 190():7-15. PubMed ID: 33321358
[TBL] [Abstract][Full Text] [Related]
8. The effect of COVID-19 on prostate cancer testing in Australia.
Jain A; Macneil J; Kim L; Patel MI
BMC Urol; 2022 Jun; 22(1):88. PubMed ID: 35729543
[TBL] [Abstract][Full Text] [Related]
9. Benefits and harms of prostate specific antigen testing according to Australian guidelines.
Caruana M; Gulati R; Etzioni R; Barratt A; Armstrong BK; Chiam K; Nair-Shalliker V; Luo Q; Bang A; Grogan P; Smith DP; O'Connell DL; Canfell K
Int J Cancer; 2024 Feb; 154(4):648-658. PubMed ID: 37819139
[TBL] [Abstract][Full Text] [Related]
10. Spatial patterns of prostate-specific antigen testing in asymptomatic men across Australia: a population-based cohort study, 2017-2018.
Kohar A; Cramb SM; Pickles K; Smith DP; Baade PD
Public Health; 2023 Apr; 217():173-180. PubMed ID: 36898290
[TBL] [Abstract][Full Text] [Related]
11. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
12. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
Tawfik A
Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
